Internal Medicine, Endocrinology, Diabetes, & Metabolism · Miami, FL
NPI
1053365551
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
11760 SW 40th St Ste 642
Miami, FL, 33175
Phone (305) 553-6744
Groups this clinician bills Medicare through
Medicare paid, 2024
$27K
308 services
Medicare patients, 2024
130
Average age 73
Drug cost, 2024
$5.9M
11,812 prescriptions
Company payments, 2025
$2,745
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Marcelo V Bendix was code 99214 (office e&m - established), 158 times for 91 patients. In total Marcelo V Bendix billed 308 services in 14 codes, and Medicare paid $27K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-07-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 158 | 91 | $101.07 | $16K |
| 99213 Office E&M - Established | Office | 74 | 51 | $68.40 | $5,062 |
| 99204 Office E&M - New | Office | 15 | 15 | $126.50 | $1,898 |
By year: 2022 $33K for 341 services; 2023 $29K for 331 services; 2024 $27K for 308 services.
Medicare prescription drug claims, 2024
In 2024, the drug Marcelo V Bendix prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,347 prescriptions and refills. In total Marcelo V Bendix wrote 11,812 Medicare prescriptions that cost $5.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,347 | 3,591 | 411 | $13K |
| Ozempic Semaglutide | 1,066 | 1,435 | 207 | $1.2M |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 669 | 969 | 160 | $731K |
| Synthroid Levothyroxine Sodium | 513 | 1,291 | 147 | $60K |
| Glipizide-Metformin Glipizide/Metformin Hcl | 449 | 900 | 138 | $17K |
| Mounjaro Tirzepatide | 423 | 510 | 87 | $537K |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 405 | 843 | 115 | $616K |
| Jardiance Empagliflozin | 331 | 584 | 103 | $344K |
| Metformin Hcl Generic | 330 | 854 | 123 | $1,161 |
| Novolog Insulin Aspart | 291 | 415 | 61 | $68K |
| Pioglitazone Hcl Generic | 259 | 598 | 80 | $2,037 |
| Janumet Sitagliptin Phos/Metformin Hcl | 229 | 322 | 60 | $172K |
| Rosuvastatin Calcium Generic | 214 | 588 | 86 | $2,186 |
| Trulicity Dulaglutide | 213 | 254 | 45 | $243K |
| Novolog Flexpen Insulin Aspart | 183 | 274 | 62 | $38K |
Brand drugs: 6,741 claims; generic drugs: 3,718 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Marcelo V Bendix $2,745 ($2,745 in general payments such as food, travel and fees) from 14 companies. The largest payer was Insulet Corporation with $1,249.
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation PODD | 81 | $1,249 |
| Novo Nordisk Inc NVO | 17 | $672 |
| Dexcom, Inc. DXCM | 2 | $237 |
| Lilly USA, LLC LLY | 11 | $169 |
| Tandem Diabetes Care, Inc. TNDM | 4 | $90.83 |
| Xeris Pharmaceuticals, Inc. | 3 | $69.99 |
| Abbvie Inc. ABBV | 3 | $56.29 |
| Corcept Therapeutics CORT | 2 | $48.08 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $38.25 |
| Recordati_rare_diseases_inc. | 1 | $34.01 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.